Outcomes
PASS, death, stroke, Cerebral Infarction, hemorrhages, groin, diabetes
ADVERSE EVENTS, STROKE, ADVERSE EVENT, CEREBRAL INFARCTION, SECONDARY, HEMORRHAGES, ATRIAL FIBRILLATION, HYPERTENSION, DIABETES
All randomized patients were evaluated with mRS on day 90 by trained research personnel blinded to transport strategy (supplementary).Secondary analyses were shifted for the following subgroups: all randomized patients, all patients with hemorrhages, all patients with stroke mimics, all patients with LVO, all ischemic patients with no LVO, and dichotomized analysis of mRS score of 0 to 2 for all patients with AIS. Excellent outcome (mRS score 0–1), and fair outcome (mRS score 0–3) were defined in post hoc analysis. Other secondary outcomes were time from onset, pick-up, and arrival at first hospital for all patients; and time to IVT (needle time) and EVT (groin puncture) for all treated patients with AIS, successful reperfusion defined as modified Treatment in Cerebral Infarction score of 2b–3, and length of CSC stay. Safety outcomes were severe dependency or death (mRS score of 5–6) in patients treated with EVT. Adverse events and severe adverse events were registered according to good clinical practice guidelines by project nurses during admission and at 90-day examination of the patient (supplementary). To measure prehospital and in-hospital delays, detailed time metrics were collected during the trial by emergency medical staff at ambulances and helicopters, and by stroke clinicians.For supplementary, we performed a not-planned subgroup analysis where effect was measured in the subgroups of age, sex, diabetes, hypertension, atrial fibrillation, PASS score, use of IVT and EVT, and presence of an LVO.